Personalized management for borderline resectable and locally advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of primary chemotherapy in patients with borderline resectable and locally advanced pancreatic cancer across Norway. Patients receive chemotherapy followed by potential surgical exploration and resection, adhering to national guidelines for treatment. The primary goal is to achieve a resection rate of 50% for borderline resectable cases and 15% for locally advanced cases, while also monitoring overall survival and postoperative outcomes. The study involves collaboration among all Norwegian centers that perform pancreatic surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)
* Nx, M0 (UICC 8th version, 2016)
* Cytological or histological confirmation of adenocarcinoma
* Age \>18 year
* Considered able to receive primary chemotherapy and possible surgery
* Written informed consent

Exclusion Criteria:

* Co-morbidity or performance status precluding primary chemotherapy
* Co-morbidity or performance status precluding pancreatectomy
* Female patients in child-bearing age not using adequate contraception, pregnant or lactating women
* Mental or physical disorders that could interfere with treatment of with the provision of informed consent
* Any reason why, in the opinion of the investigator, the patient should not participate

Where it's running

• Oslo University Hospital
  Oslo, Norway Recruiting
• Haukeland University Hospital
  Bergen, Norway, Norway Not yet recruiting
• Stavanger University Hospital
  Stavanger, Norway, Norway Not yet recruiting
• University Hospital of North Norway
  Tromsø, Norway, Norway Not yet recruiting
• St. Olavs Hospital, Trondheim University Hospital
  Trondheim, Norway, Norway Not yet recruiting

Study contacts

• Study coordinator: Knut Jørgen Labori, MD PhD
• Email: uxknab@ous-hf.no
• Phone: +4723070000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemotherapy With IMD10 (Focused Ultrasound) for Borderline Resectable or Locally Advanced Pancreatic Cancer

  This trial tests whether adding IMD10 focused ultrasound to a standard chemotherapy regimen helps people with borderline resectable or locally advanced pancreatic cancer see better survival.

  Recruiting IMGT Co., Ltd. · Boston, Massachusetts and 4 other locations · NCT07325214

• Pancreatic Surgery and New Diabetes Risk in Adults without Diabetes

  This study tests whether removing part or all of the pancreas during surgery affects blood sugar control and metabolism in adults who did not have diabetes before the operation.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome · NCT07608055

• Adding silibinin to standard daunorubicin or idarubicin therapy for newly diagnosed non‑M3 acute myeloid leukemia

  This trial will test whether adding silibinin (a liver‑protecting compound) to standard daunorubicin or idarubicin chemotherapy helps people with newly diagnosed non‑M3 acute myeloid leukemia.

  Recruiting Phase 4 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07561892

• PancreasPlus app for monitoring recovery, symptoms, and education after pancreatic cancer treatment

  This project will test whether the PancreasPlus app helps adults with pancreatic cancer and their caregivers monitor symptoms, get timely information, and communicate with their healthcare team.

  Recruiting Casa di Cura Dott. Pederzoli · Pavia, Pavia and 1 other locations · NCT07532590

• Hybrid Closed-Loop Insulin Delivery After Pancreatectomy

  This study tests whether a commercially available monohormonal hybrid closed-loop insulin delivery system can help adults who developed diabetes after pancreatectomy better manage blood sugar.

  Recruiting Centre Hospitalier Sud Francilien · Corbeil-Essonnes, France and 1 other locations · NCT07430293

• Chemotherapy followed by ablative SBRT for locally advanced inoperable pancreatic cancer

  This trial will try chemotherapy followed by high-dose focused radiation (SBRT) as the first treatment for adults with locally advanced, inoperable pancreatic cancer.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07407231

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.